» Articles » PMID: 35949620

Shikonin Inhibits the Proliferation of Cervical Cancer Cells Via FAK/AKT/GSK3β Signalling

Overview
Journal Oncol Lett
Specialty Oncology
Date 2022 Aug 11
PMID 35949620
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer is one of the most lethal malignancies of the female reproductive system. Shikonin, a naphthoquinone pigment extracted from the traditional medicinal herb, , has been demonstrated to exert significant inhibitory effects on a variety of tumours and In the present study, the effects of shikonin on cervical cancer and the underlying mechanisms were investigated. The effects of shikonin on the viability on HeLa and SiHa cervical cancer cells was examined using cell counting kit (CCK-8) and colony formation assays. Immunofluorescence assay was performed to detect the levels of the proliferation-related protein, Ki67. Western blot analysis was utilized to measure the phosphorylated and total expression levels of proteins, including focal adhesion kinase (FAK), AKT, and glycogen synthase kinase 3β (GSK3β). Cell migration was determined by using wound healing assay. Metastasis-associated 1 (MTA1), TGFβ1 and VEGF mRNA expression levels were determined using reverse transcription-quantitative PCR. It was demonstrated that, shikonin inhibited cervical cancer cell proliferation and migration. The data of the present study revealed that shikonin inhibited the proliferation of HeLa and SiHa cells in a concentration- and time-dependent manner. Mechanistically, shikonin blocked the proliferation of cervical cancer cells by downregulating the phosphorylation of FAK, AKT and GSK3β induced by EGF. In addition, shikonin significantly suppressed cell migration and reduced the expression of migration-related proteins, including MTA1, TGFβ1 and VEGF. On the whole, the present study demonstrates that shikonin may exert an inhibitory effect on the cervical cancer cell proliferation and migration through the FAK/AKT/GSK3β signaling pathway. These findings suggest that shikonin may function as a potential therapeutic drug for the treatment of cervical cancer.

Citing Articles

Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species.

Qi K, Li J, Hu Y, Qiao Y, Mu Y Front Pharmacol. 2024; 15:1416781.

PMID: 39076592 PMC: 11284502. DOI: 10.3389/fphar.2024.1416781.

References
1.
Zhang Y, Sun B, Huang Z, Zhao D, Zeng Q . Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1. Med Sci Monit. 2018; 24:661-670. PMC: 5804303. DOI: 10.12659/msm.908381. View

2.
Rao Y, Wang H, Fan L, Chen G . Silencing MTA1 by RNAi reverses adhesion, migration and invasiveness of cervical cancer cells (SiHa) via altered expression of p53, and E-cadherin/β-catenin complex. J Huazhong Univ Sci Technolog Med Sci. 2011; 31(1):1-9. DOI: 10.1007/s11596-011-0141-9. View

3.
Bhatla N, Aoki D, Sharma D, Sankaranarayanan R . Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018; 143 Suppl 2:22-36. DOI: 10.1002/ijgo.12611. View

4.
Pilleron S, Cabasag C, Ferlay J, Bray F, Luciani S, Almonte M . Cervical cancer burden in Latin America and the Caribbean: Where are we?. Int J Cancer. 2020; 147(6):1638-1648. DOI: 10.1002/ijc.32956. View

5.
Wu Z, Wu L, Li L, Tashiro S, Onodera S, Ikejima T . Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis. J Asian Nat Prod Res. 2004; 6(3):155-66. DOI: 10.1080/1028602032000169622. View